Altered Cortisol Metabolism Increases Nocturnal Cortisol Bioavailability in Prepubertal Children With Type 1 Diabetes Mellitus.
11-beta-Hydroxysteroid Dehydrogenase Type 1
/ metabolism
11-beta-Hydroxysteroid Dehydrogenase Type 2
/ metabolism
3-Oxo-5-alpha-Steroid 4-Dehydrogenase
Anxiety
/ psychology
Child
Cortisone
/ metabolism
Depression
/ psychology
Diabetes Mellitus, Type 1
/ metabolism
Female
Glucocorticoids
/ urine
Humans
Hydrocortisone
/ metabolism
Male
Membrane Proteins
Saliva
/ chemistry
11β-hydroxy steroid dehydrogenase-1
5α-Reductase
children
glucocorticoids
type 1 diabetes
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
07
2021
accepted:
22
11
2021
entrez:
31
12
2021
pubmed:
1
1
2022
medline:
17
2
2022
Statut:
epublish
Résumé
Disturbances in the activity of the hypothalamus-pituitary-adrenal axis could lead to functional alterations in the brain of diabetes patients. In a later perspective of investigating the link between the activity of the hypothalamus-pituitary-adrenal axis and the developing brain in children with diabetes, we assessed here nocturnal cortisol metabolism in prepubertal children with type 1 diabetes mellitus (T1DM). Prepubertal patients (aged 6-12 years) diagnosed with T1DM at least 1 year previously were recruited, along with matched controls. Nocturnal urine samples were collected, with saliva samples taken at awakening and 30 minutes after awakening. All samples were collected at home over 5 consecutive days with no detectable nocturnal hypoglycaemia. The State-Trait Anxiety Inventory (trait scale only) and Child Depression Inventory were also completed. Glucocorticoid metabolites in the urine, salivary cortisol (sF) and cortisone (sE) were measured by liquid chromatography-tandem mass spectrometry. Metabolic data were analysed by logistic regression, adjusting for sex, age, BMI and trait anxiety score. Urine glucocorticoid metabolites were significantly lower in T1DM patients compared to controls. 11β-hydroxysteroid dehydrogenase type 1 activity was significantly higher, while 11β-hydroxysteroid dehydrogenase type 2, 5(α+β)-reductase and 5α-reductase levels were all lower, in T1DM patients compared to controls. There was a significant group difference in delta sE level but not in delta sF level between the time of awakening and 30 minutes thereafter. Our findings suggest that altered nocturnal cortisol metabolism and morning HPA axis hyperactivity in children with T1DM leads to greater cortisol bioavailability and lower cortisol production as a compensatory effect. This altered nocturnal glucocorticoid metabolism when cortisol production is physiologically reduced and this HPA axis hyperactivity question their impact on brain functioning.
Identifiants
pubmed: 34970219
doi: 10.3389/fendo.2021.742669
pmc: PMC8712331
doi:
Substances chimiques
Glucocorticoids
0
Membrane Proteins
0
11-beta-Hydroxysteroid Dehydrogenase Type 1
EC 1.1.1.146
11-beta-Hydroxysteroid Dehydrogenase Type 2
EC 1.1.1.146
3-Oxo-5-alpha-Steroid 4-Dehydrogenase
EC 1.3.99.5
SRD5A2 protein, human
EC 1.3.99.5
Cortisone
V27W9254FZ
Hydrocortisone
WI4X0X7BPJ
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
742669Informations de copyright
Copyright © 2021 Brossaud, Corcuff, Vautier, Bergeron, Valade, Lienhardt, Moisan and Barat.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Endocrinol Metab. 1995 Oct;80(10):3002-8
pubmed: 7559888
Steroids. 2006 Jul;71(7):591-8
pubmed: 16616286
J Clin Endocrinol Metab. 2002 Dec;87(12):5587-93
pubmed: 12466357
Diabetes. 2014 Jul;63(7):2244-52
pubmed: 24931032
J Clin Endocrinol Metab. 1999 Sep;84(9):3316-21
pubmed: 10487705
Am J Clin Nutr. 2003 Mar;77(3):731-6
pubmed: 12600869
Curr Diabetes Rev. 2016;12(3):165-78
pubmed: 25981499
J Endocrinol. 2014 Aug;222(2):257-66
pubmed: 24872577
Diabetes Care. 2015 Mar;38(3):453-9
pubmed: 25650362
Psychoneuroendocrinology. 2018 Jul;93:72-81
pubmed: 29702445
Endocrinology. 2010 Oct;151(10):5030-7
pubmed: 20810561
World J Diabetes. 2015 Mar 15;6(2):259-70
pubmed: 25789107
Physiol Rev. 2013 Jul;93(3):1139-206
pubmed: 23899562
J Clin Endocrinol Metab. 2003 Dec;88(12):5907-13
pubmed: 14671189
Eur J Clin Invest. 2003 Jul;33(7):589-94
pubmed: 12814396
Front Endocrinol (Lausanne). 2017 Apr 18;8:81
pubmed: 28458655
Pediatr Diabetes. 2008 Jul 28;9(4 Pt 1):308-11
pubmed: 18466212
Cell Metab. 2008 Apr;7(4):286-7
pubmed: 18396133
Neuroimmunomodulation. 2008;15(1):61-7
pubmed: 18667801
Ann N Y Acad Sci. 2006 Nov;1083:165-84
pubmed: 17148739
Nat Neurosci. 2008 Mar;11(3):309-17
pubmed: 18278039
J Clin Endocrinol Metab. 2019 Jun 1;104(6):2239-2249
pubmed: 30657922
Psychiatry Res. 1990 Jan;31(1):31-7
pubmed: 2156275
Nat Rev Neurosci. 2009 Jun;10(6):434-45
pubmed: 19401723
Front Psychiatry. 2019 Feb 28;10:101
pubmed: 30890970
Metabolism. 1993 Jun;42(6):696-700
pubmed: 8389960
Nat Rev Neurosci. 2017 Jan;18(1):7-19
pubmed: 27881856
Diabetes. 2008 Oct;57(10):2652-60
pubmed: 18633104
Lancet Neurol. 2008 Feb;7(2):184-90
pubmed: 18207116
Clin Endocrinol (Oxf). 2000 Apr;52(4):403-11
pubmed: 10762282
Diabetes Metab. 2013 Apr;39(2):163-8
pubmed: 23159804
Biochem J. 1996 Jul 15;317 ( Pt 2):621-5
pubmed: 8713094
J Endocr Soc. 2019 Jun 26;3(8):1631-1640
pubmed: 31403090
Mol Cell Endocrinol. 2011 Feb 10;333(1):62-9
pubmed: 21163329